GYNIX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GYNIX (GYNIX).
Coagulative necrosis of tissue via trichloroacetic acid; chemical cauterization of epithelial cells.
| Metabolism | Not metabolized; acts locally via direct chemical action. |
| Excretion | Primarily renal (approximately 60-80% as unchanged drug) and biliary (20-30% as metabolites; unchanged drug not detected in bile). Fecal elimination accounts for <5%. |
| Half-life | Terminal half-life is 2.5-3 hours in patients with normal renal function; prolonged to 6-8 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 12-15 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 20-30% bound to albumin with negligible binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent Vd is 0.8-1.1 L/kg (range 0.6-1.3 L/kg), indicating extensive tissue distribution (e.g., lung, liver, bone). |
| Bioavailability | Oral: 85-95% (immediate-release) and 70-80% (sustained-release due to first-pass effect). Vaginal: 5-10% (minimal systemic absorption). IV: 100%. |
| Onset of Action | Oral: 30-60 minutes; IV: 5-10 minutes (rapid antibacterial effect); Topical (vaginal): within 1 hour (local effect). |
| Duration of Action | Oral: 8-12 hours (sustained release formulation provides 24-hour coverage); IV: 12 hours; Topical: 24 hours (single dose). Clinical note: Extended duration due to high tissue penetration. |
1 vaginal tablet (100 mg) once daily at bedtime for 7 days
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min: use with caution, consider alternative therapy. |
| Liver impairment | Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe (Child-Pugh C): contraindicated. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No dose adjustment required; use same as adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GYNIX (GYNIX).
| Breastfeeding | No data on excretion in human milk. Expected minimal systemic absorption. Use caution if applied to breast area. M/P ratio unknown. |
| Teratogenic Risk | First trimester: Inadequate human data; animal studies not available. Theoretical risk based on pharmacologic action. Second and third trimesters: No known fetal harm from topical use. Systemic absorption minimal. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to trichloroacetic acid; pregnancy (relative); use on malignant tissue.
| Precautions | Avoid contact with normal tissue; risk of chemical burns; not for use on neoplastic lesions. |
Loading safety data…
| No specific monitoring required. Observe for local irritation or allergic reaction. |
| Fertility Effects | No known effects on fertility. Not systemically absorbed significantly. |